Ibrutinib (Imbruvica®). HTA ID: 20032

Assessment Status Rapid Review Complete
HTA ID 20032
Drug Ibrutinib
Brand Imbruvica®
Indication As a single agent or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Assessment Process
Rapid review commissioned 06/07/2020
Rapid review completed 04/08/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Ibrutinib as a single agent or in combination with obinutuzumab for adult patients with previously untreated CLL compared with the current standard of care.